Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

p>General and administrative 2,951 1,813 7,749 6,087

Total cost and expenses 5,744 4,835 17,020 17,029

Operating loss (5,037) (2,185) (15,692) (8,669)

Interest and other

income, net 63 159 381 548

Interest expense (450) (187) (1,515) (862)

Gain on extinguishment

of debt 16,127 - 16,127 219

Net income (loss) 10,703 (2,213) (699) (8,764)

Deemed dividend from

beneficial conversion

feature for Series F

redeemable convertible

preferred stock - - - (13,842)

Accretion of dividends

on preferred stock (441) - (1,167) (867)

Reversal of accretion

of dividends on

preferred stock not paid - - - 4,919

Net loss attributed to

common stockholders $10,262 $(2,213) $(1,866) $(18,554)

Net loss per share:

- Basic and diluted $3.94 $(0.24) $(0.72) $(3.16)

Shares used in computing

net loss per share:

- Basic and diluted 2,606,739 9,070,994 2,599,425 5,868,131

ImaRx Therapeutics, Inc.

Selected Balance Sheet Data (in thousands)

December 31 December 31

2006 2007

ASSETS

Current assets:

Cash and cash equivalents $4,256 $12,861

Restricted cash - 388

Accounts receivable, net 576 349

Inventory
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... - Continued Advancement Toward ...   Shire (LSE: SHP, NASDAQ: SHPG ... March 31, 2015. Financial Highlights Q1 ... Total revenues $1,488 million +11% +15% Non GAAP operating ... from continuing operations $475 million +55% Non GAAP EBITDA ...
(Date:4/30/2015)... SAINT-MALO, FRANCE (PRWEB) April 30, 2015 ... States, and at http://www.lespausa.com , ... a multi-action product combining the benefits of makeup, ... formula. This subtly tinted cream is designed with ... blemishes for an even complexion and a healthy ...
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 SureClinical, ... that Julie I. Morris has joined SureClinical’s executive team ... an experienced biotech and technology executive with over 25 ... Fortune 500 companies. , Ms. Morris joins SureClinical ... biotech company. She was CFO of MBI from its ...
(Date:4/30/2015)... WA (PRWEB) April 30, 2015 ... developed ultrafiltration membranes, the PX, PY, and ... coupons, sheets, and disks. Designed to be ... these new membranes can fill critical process requirements ... hinder downstream processes. , “New regulations on industrial ...
Breaking Biology Technology:Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Sterlitech Offers New Ultrafiltration Membranes 2
... Holdings Co.,Ltd. (NYSE: STP ), one of the world,s ... management is scheduled to,participate in the following upcoming investor conferences ... 3-7, 2007 at the Fiera Milano ... Conference on September 6, 2007 at Le ...
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) ... has shipped a CT Laser Mammography,(CTLM(R)) system to ... the first such scanner in the country. ... system will be installed at UPM,s academic facility ...
... Sept. 4 Human Genome,Sciences, Inc. (Nasdaq: ... the,BioCentury - Thomson Financial 14th Anniversary NewsMakers in ... be accessed at, http://www.hgsi.com . (Logo: ... Human Genome Sciences, senior management team will present,an ...
Cached Biology Technology:Suntech to Attend Upcoming Investor Conferences and Industry Events 2Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia 2
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... new policy paper by Rice University,s Baker Institute for ... and influence of noncommercial traders, or "speculators," in the ... Commodities Futures Modernization Act of 2000. Speculators now constitute ... the U.S. oil futures market, compared with only about ...
... PITTSBURGH, Aug. 26 An exploration of the molecular links ... target for diabetes treatment, say scientists at the John G. ... Their findings were published earlier this month in the online ... the American Diabetes Association. Signs of low-grade systemic ...
... fond of talking about it as are politicians, economists ... The problem is that the term sustainability can refer ... at the Technische Universitaet Muenchen have shed light on ... science they have managed to give the term "sustainability" ...
Cached Biology News:Study: Oil speculators dominate open interest in oil futures 2Study: Oil speculators dominate open interest in oil futures 3Pitt study finds molecular link between insulin resistance and inflammation 2New tools for sustainable farming 2New tools for sustainable farming 3
Ezrin/Radixin/Moesin Antibody...
Ezrin/Radixin/Moesin Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: